Funding · Healthcare & Life Sciences

MedVital raises ₹18 crore growth funding

What they do

MedVital makes advanced wound care and regenerative aesthetic products

It raised ₹18 crore in growth funding led by Alkemi Growth Capital

The company supplies to over 200 hospitals and plans to expand operations

MedVital raised ₹18 crore in growth funding.
The round was led by Alkemi Growth Capital.
Other participants included Dr Sanjay Arora, Shubhan Ventures, and existing investors.
The company will use the funds to expand operations and accelerate product development.
It also plans to build capabilities across devices, biomaterials, and biologics.
MedVital aims to improve supply chain efficiency and unit economics.

Advanced wound care adoption in India is still at an early stage despite clinical need.
MedVital operates at the intersection of medical technology and aesthetics.
The company is building a portfolio across multiple healthcare segments.

MedVital was founded in 2024.
It focuses on advanced wound care, regenerative aesthetics, and chronic skin conditions.
Its product NoWound includes NPWT (negative pressure wound therapy) and a chitosan-based liquid bandage for hospitals.
Its product Elyara offers non-invasive skin and hair restoration using peptide-led signalling and regenerative pathways.
The company supplies to over 200 corporate and public healthcare institutions in India.
It reports strong repeat usage from hospitals.

Expand operations and accelerate product development.
Build capabilities across devices, biomaterials, and biologics.
Improve supply chain efficiency and unit economics.
Expand hospital footprint and invest in clinical education and evidence-led adoption.

Product: A full-stack platform for wound care and minimally invasive aesthetics, including NPWT devices and biomaterial-based products.
Customers: Hospitals, clinics, and home-care settings.
How it makes money: Sells medical devices and related products to healthcare providers.
What sets it apart: Combines monitoring with next-generation biomaterials and locally manufactured devices.
Operations: Expanding product lines in wound care, biomaterials, biologics, and regenerative skin applications.